Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial

Trial Profile

Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Imiquimod (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
  • Indications HIV infections; Immunocompromised infections; Influenza virus infections
  • Focus Pharmacodynamics
  • Acronyms IMIFLU
  • Most Recent Events

    • 15 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top